Novo Nordisk Licenses GKA Program To Innovator TransTech
This article was originally published in The Pink Sheet Daily
Executive Summary
Deal is part of Novo’s effort to focus on protein-based molecules.
You may also be interested in...
Forest Jumps Back Into Diabetes In Deal With TransTech For Glucokinase Activators
Forest agreed to pay $50 million upfront for rights to several compounds in a novel class of drugs, including a lead drug that is Phase II-ready.
Forest Jumps Back Into Diabetes In Deal With TransTech For Glucokinase Activators
Forest agreed to pay $50 million upfront for rights to several compounds in a novel class of drugs, including a lead drug that is Phase II-ready.
Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins
Small molecule projects in development will be out-licensed, including the Phase I glucokinase activator NN9101.